The breast cancer trial landscape in 2026
Breast cancer is one of the most commercially active oncology therapeutic areas. The ADC wave, following trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan, has spawned dozens of follow-on programs across HER2 expression levels and triple-negative disease. CDK4/6 inhibitor combinations continue expanding into earlier lines and adjuvant settings. PARP inhibitors are extending into BRCA-mutated early-stage disease. The pipeline is wide and fast-moving.
For oncology-focused pharma and biotech professionals, keeping up with the breast cancer clinical trial pipeline manually is effectively impossible. New trials register continuously, trial status changes daily, and the sub-type stratification (HER2+, HER2-low, TNBC, HR+HER2-) means a single "breast cancer" search returns an unmanageable volume of undifferentiated results.
Key programs and mechanisms to monitor in breast cancer:
- HER2-positive: Next-generation anti-HER2 ADCs, bispecific antibodies targeting HER2, TKI combinations, and tucatinib-based regimens
- Triple-negative (TNBC): PD-1/PD-L1 combinations, TROP2-targeting ADCs, PARP inhibitor combinations in BRCA-mutated TNBC
- HR+ HER2-negative: CDK4/6 inhibitor combinations beyond approved settings, PI3K/AKT/mTOR targeting, ESR1 mutation-directed therapies
- HER2-low: T-DXd successors and competitive ADC programs exploiting low HER2 expression
- Early stage: Neoadjuvant and adjuvant programs, de-escalation trials, immunotherapy in early TNBC
- BRCA/HRD-mutated: PARP inhibitor combinations, DNA damage response pathway targeting
Get daily breast cancer trial digest
Filtered by subtype, phase, and sponsor. Clean daily digest. Free plan, no credit card required.
Get the Free DigestA primary completion date pushed out, enrollment cut, or a primary endpoint changed in the last 90 days. Active trials only.
| Trial | Warning signs | Status |
|---|---|---|
| Metastasis-directed Therapy for Oligometastases of Breast Cancer NCT06135714 | Primary completion moved at least 3 years later Enrollment reduced 57% | Recruiting |
270 more on the Trials at Risk page. See which trials →
Phase 2 and Phase 3 trials with a primary completion date in the next 180 days, as ClinicalTrials.gov estimates it today. Active trials only.
| Trial | Scheduled | Phase |
|---|---|---|
| JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast… NCT06846437 | Oct 13, 2026 · Estimated | Phase 3 |
261 more on the Completions page. See the calendar →
What DataLookout monitors for breast cancer
Configure your profile with condition and mechanism keywords as specific or broad as your intelligence needs require. Examples:
- By subtype: "HER2-positive breast cancer", "triple-negative breast cancer", "TNBC", "HR-positive breast cancer", "HER2-low"
- By mechanism: "CDK4/6 inhibitor", "PARP inhibitor", "antibody-drug conjugate", "ADC", "TROP2", "PI3K"
- By setting: "metastatic breast cancer", "early-stage breast cancer", "neoadjuvant", "adjuvant"
- Phase filter: Phase 2/3 for competitive intelligence, or all phases for comprehensive coverage
- Sponsor filter: Industry-sponsored programs for BD relevance, or all sponsors for full pipeline view
What DataLookout adds to ClinicalTrials.gov
ClinicalTrials.gov RSS feeds tell you that a study record was updated. DataLookout compares each record against the previous day across 13 tracked fields and tells you which one changed, with the old and new values, for every Breast Cancer trial on your watchlist. Each change is marked Stopped, Notable or Minor, so a trial being terminated does not read the same as a few sites being added.
Who uses breast cancer trial monitoring
Oncology business development and strategy teams
Companies active in breast cancer track new competitive entries, Phase 2/3 transitions, and trial terminations to inform licensing decisions and pipeline strategy. The ADC space alone has dozens of programs competing for overlapping patient populations. Knowing which new ADC programs are entering Phase 2, and what their differentiation claim is, shapes strategic planning for any HER2 or TNBC franchise holder.
Breast cancer biotech analysts and investors
Investors covering oncology use trial registrations as leading indicators. A Phase 3 start for a next-generation CDK4/6 combination or a pivotal TNBC ADC study can precede significant valuation events. Daily monitoring of new trial registrations ensures no signal is missed before it becomes widely reported.
Medical affairs professionals at breast cancer companies
Medical affairs teams track competitors' clinical programs to anticipate label changes, prepare for new market entrants, and inform key opinion leader engagement. In a field where multiple approved CDK4/6 inhibitors compete and the HER2 landscape is evolving rapidly, real-time awareness of competitive pipeline developments is essential.
Breast cancer patient advocacy organizations
Organizations like BCRF, Susan G. Komen, and metastatic breast cancer-focused foundations use clinical trial awareness to connect patients with appropriate studies, particularly patients with TNBC or metastatic disease who need options beyond current standard of care.
Frequently asked questions
4239 active trials, 2278 recruiting.
Industry sponsors run 716 of these trials. The rest are run by universities, hospitals, government bodies and other non-commercial sponsors. The table below lists the 5 largest of 347.
| Top industry sponsor | Active trials |
|---|---|
| AstraZeneca | 51 |
| Novartis Pharmaceuticals | 33 |
| Pfizer | 30 |
| Roche / Genentech | 30 |
| Eli Lilly and Company | 22 |
| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination… NCT05069038 | Active, Not Recruiting | Primary completion date changed from estimate of Sep 2026 to Jun 22, 2026 | 2026-10-10 |
| Decision Making Tool in Supporting Decision Making in Contralateral… NCT02918474 | Recruiting | Completion pushed from Sep 30, 2026 to Sep 30, 2028 | 2026-10-10 |
| BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2… NCT05977036 | Recruiting | Interventions modified | 2026-10-10 |
| Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors… NCT04152499 | Active, Not Recruiting | Completion pushed from Dec 31, 2026 to Nov 30, 2027 | 2026-10-10 |
| Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With… NCT06757634 | Recruiting | Trial sites expanded: 203 → 239 locations | 2026-10-10 |
Each trial page shows every change DataLookout has recorded for that trial.
DataLookout checks ClinicalTrials.gov every day and records what changed on each trial: status, enrollment, phase, primary endpoint, completion dates, sites, sponsor, and the stated reason a trial stopped. Add a sponsor or a disease to your watchlist, or save any search, and the changes arrive in a daily or weekly email digest.
Free, $0 forever: 1 sponsor + 1 disease watchlist, 1 saved search in your email digest, track up to 5 individual trials, daily change detection, Trials at Risk (top 2 trials), the weekly report (top 3 trials). No credit card.
Pro, $49/month or $490/year: 10 sponsor + 10 disease watchlists, 10 saved searches in your email digest, track up to 25 individual trials, full Trials at Risk list, Completions calendar, the full weekly report, landscape reports, CSV export.